Wednesday, September 9  4 Total

Exciting New Developments for Treating MDS

Exciting New Developments for Treating MDS

At last… Exciting New Developments for Treating MDS. Drs. Garcia-Manero and Komrokji discuss two recently approved therapeutic options and continued research.
New Induction Approaches and Measurable Residual Disease in AML

New Induction Approaches and Measurable Residual Disease in AML

What’s on the horizon for AML? Drs. Pollyea and Ravandi offer insights on what to watch for in the coming years.
Evolving Induction Strategies and the Role of Maintenance Therapy in AML

Evolving Induction Strategies and the Role of Maintenance Therapy in AML

Evolving Strategies for AML. Drs. Ravandi and Pollyea discuss recent phase III VIALE-A and QUAZAR trials and their clinical impact on treatment paradigms.
Emerging Therapeutics for Higher-Risk MDS

Emerging Therapeutics for Higher-Risk MDS

What’s coming for higher-risk MDS? Drs. Garcia-Manero and Komrokji discuss some promising agents in the rich MDS pipeline.

Thursday, September 10  2 Total

Therapeutic Choices, Better Outcomes, and Unanswered Questions in ALL

Therapeutic Choices, Better Outcomes, and Unanswered Questions in ALL

What’s Next for ALL? Drs. Jabbour and Luger discuss exciting therapeutic advances and key areas for clinical research.
Clinical Opportunities for Novel MPN Therapies

Clinical Opportunities for Novel MPN Therapies

Novel MPN Therapies in Practice: Drs. Rampal and Hobbs assess evolving treatment paradigms for MPNs.

Friday, September 11  4 Total

The Emerging Role of BCMA-Targeted Therapies in Multiple Myeloma

The Emerging Role of BCMA-Targeted Therapies in Multiple Myeloma

What’s next for myeloma? Drs. Voorhees and Martin discuss progress with BCMA-targeted therapies.
Clinical Implications from Recent Trials in Multiple Myeloma

Clinical Implications from Recent Trials in Multiple Myeloma

Highlights from Recent MM Clinical Trials – Drs. Martin and Voorhees focus on recent studies evaluating newer therapies in earlier lines of therapy.
The Future of CAR-T Cell Therapy for Aggressive Lymphomas

The Future of CAR-T Cell Therapy for Aggressive Lymphomas

CAR-T Cells for Aggressive Lymphomas. Drs. Noy and Riedell offer a glimpse of what’s to come.
2020 Update in Therapeutics for Aggressive Lymphomas

2020 Update in Therapeutics for Aggressive Lymphomas

New Therapies for DLBCL: Drs. Riedell and Noy highlight recent drug approvals.

Saturday, September 12  0 Total